The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction

Sponsor
Saglik Bilimleri Universitesi (Other)
Overall Status
Completed
CT.gov ID
NCT04751474
Collaborator
(none)
93
1
2
1.9
48.8

Study Details

Study Description

Brief Summary

The Covid-19 pandemic has affected global health systems and required healthcare professionals to show high performance. In this process, the mental health of intensive care nurses, who undertake the biggest burden in health systems, is negatively affected by the high working hours and patient care burden during the pandemic. When the literature is reviewed, pessimistic thinking, feeling hopeless and not enjoying life at more exacerbated levels can be observed in intensive care nurses. It is concluded that studies are needed to increase the motivation of intensive care nurses during the Covid-19 pandemic.In this study, it was aimed to evaluate the effect of motivational messages on optimism, hopelessness and life satisfaction of intensive care nurses during the Covid-19 pandemic.

Condition or Disease Intervention/Treatment Phase
  • Other: Motivational messages
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
93 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction of Intensive Care Nurses During the COVID-19 Pandemic : A Randomized Controlled Study
Actual Study Start Date :
Feb 1, 2021
Actual Primary Completion Date :
Mar 1, 2021
Actual Study Completion Date :
Mar 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Motivational messages

Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.

Other: Motivational messages
Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.

No Intervention: Control group

The control group did not receive any intervention.

Outcome Measures

Primary Outcome Measures

  1. Optimistic level assessed by the Life Orientation Test [21 days after from baseline]

    The primary endpoint of this study was the difference between groups in terms of Life Orientation Test scores 21 days after. The scale consists of a total of 10 items. The range of scores obtained from the scale varies between 6-30 points. Low scores indicate pessimism, while high scores indicate optimism.

  2. Hopelessness level assessed by the Beck Hopelessness Scale [21 days after from baseline]

    The primary endpoint of this study was the difference between groups in terms of Beck Hopelessness Scale scores 21 days after. The scale consists of a total of 20 items..The range of scores obtained from the scale varies between 0-20 points. High scores indicate that the level of hopelessness is also high.

  3. Life satisfaction assessed by the Satisfaction with Life Scale [21 days after from baseline]

    The primary endpoint of this study was the difference between groups in terms of Satisfaction with Life Scale scores 21 days after. The scale consists of a total of 5 items.The range of scores obtained from the scale varies between 5-25 points. As the total score obtained from the scale increases, life satisfaction level also increases.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • agreeing to participate in the study

  • being a nurse

  • working in intensive care during the COVID-19 pandemic

Exclusion Criteria:
  • underfilling or not fill out forms and scales

Contacts and Locations

Locations

Site City State Country Postal Code
1 Elif Gezginci Istanbul Turkey 34668

Sponsors and Collaborators

  • Saglik Bilimleri Universitesi

Investigators

  • Principal Investigator: Elif Gezginci, RN, PhD, Saglik Bilimleri Universitesi

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Elif Gezginci, Principal Investigator, Saglik Bilimleri Universitesi
ClinicalTrials.gov Identifier:
NCT04751474
Other Study ID Numbers:
  • 2021/47-31
First Posted:
Feb 12, 2021
Last Update Posted:
Apr 20, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Apr 20, 2021